146 related articles for article (PubMed ID: 9129016)
1. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
[TBL] [Abstract][Full Text] [Related]
3. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy.
Prósper F; Solá C; Hornedo J; Arbona C; Menéndez P; Orfao A; Lluch A; Cortés-Funes H; López JJ; García-Conde J
Leukemia; 2003 Feb; 17(2):437-41. PubMed ID: 12592344
[TBL] [Abstract][Full Text] [Related]
5. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
[TBL] [Abstract][Full Text] [Related]
6. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
7. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
[TBL] [Abstract][Full Text] [Related]
8. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
10. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
Basser RL; To LB; Begley CG; Maher D; Juttner C; Cebon J; Mansfield R; Olver I; Duggan G; Szer J; Collins J; Schwartz B; Marty J; Menchaca D; Sheridan WP; Fox RM; Green MD
J Clin Oncol; 1998 May; 16(5):1899-908. PubMed ID: 9586908
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.
Weaver A; Chang J; Wrigley E; de Wynter E; Woll PJ; Lind M; Jenkins B; Gill C; Wilkinson PM; Pettengell R; Radford JA; Collins CD; Dexter TM; Testa NG; Crowther D
J Clin Oncol; 1998 Aug; 16(8):2601-12. PubMed ID: 9704709
[TBL] [Abstract][Full Text] [Related]
12. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma.
Pettengell R; Testa NG; Swindell R; Crowther D; Dexter TM
Blood; 1993 Oct; 82(7):2239-48. PubMed ID: 7691253
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
15. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
[TBL] [Abstract][Full Text] [Related]
18. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
Lickliter JD; Begley CG; Boyd AW; Szer J; Grigg AP
Leuk Lymphoma; 1994 Sep; 15(1-2):91-7. PubMed ID: 7532059
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients.
Glaspy JA; Shpall EJ; LeMaistre CF; Briddell RA; Menchaca DM; Turner SA; Lill M; Chap L; Jones R; Wiers MD; Sheridan WP; McNiece IK
Blood; 1997 Oct; 90(8):2939-51. PubMed ID: 9376574
[TBL] [Abstract][Full Text] [Related]
20. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Kröger N; Zeller W; Fehse N; Hassan HT; Krüger W; Gutensohn K; Lölliger C; Zander AR
Br J Haematol; 1998 Sep; 102(4):1101-6. PubMed ID: 9734664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
